A Once-in-a-Lifetime Opportunity in Healthcare Is Here

Healthcare is going through a major transition phase and is ripe for innovation, that much we know for sure. We also know that innovation comes from talented leadership, backed by smart investors.

iSelect is working with industry experts to accelerate this transition, partnering with leading medical professionals and institutions to help make promising healthcare innovations a reality. Our approach is based around the simple idea that true change in health and medicine is going to come from the inside, from the doctors, researchers, and other healthcare professionals who are doing this work every day.

We want to partner with them. We want to support their ideas. We want to help their companies grow.

We work with major research centers to find the most promising opportunities, and we work with doctors to match our diligence and deal sourcing with their medical expertise to back the select few companies with the most promise. So far, this includes companies focused on chronic pain, cancer, epilepsy, pulmonary fibrosis and more.

They are the experts in healthcare. iSelect is the expert in venture investing. Together we can solve this problem.

Join our healthcare market network.

iSelect Companies

Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis Technology (PASAT). The first application, PrevisEA, is a noninvasive, disposable, self-contained device that is clinically proven to predict postoperative ileus (POI) in surgical patients.
Learn more… Account Required

Cofactor Genomics uses proprietary RNA sequencing technology and machine learning algorithms to diagnose disease. RNA serves as a real-time barometer of a person’s health, as opposed to DNA which remains little changed throughout a person’s life and whose analysis is estimated to diagnose less than 5% of diseases. Compared to current methods, Cofactor’s patent pending RNA isolation technology allows the Company to detect specific RNA molecules from low-quality tissue samples, making 100x more patient specimens available for analysis.
Learn more… Account Required

Neuros Medical, Inc., a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Altius® Electrical Nerve Block, is focused on elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Learn more… Account Required

Indalo Therapeutics (formerly known as Antegrin Therapeutics, Inc.), based in St. Louis, MO is a biopharmaceutical company developing and testing novel compounds that inhibit the development of pulmonary (lung) fibrosis and other fibrotic diseases by inhibiting proteins that are the key drivers of the fibrotic process. Uncontrolled, fibrosis can cause diseased organs to stop functioning.
Learn more… Account Required

Gila is developing a treatment for obesity using naturally occurring hormones (PYY) known to induce satiety, leading to weight loss. Gila is developing formulations to be applied to the tongue prior to meals, which have successfully induced satiety in animal testing without causing the nausea like symptoms associated with injectable and other formulations.
Learn more… Account Required

Euclises Pharmaceuticals is developing and testing novel cyclooxygenase-2 (COX-2, an enzyme responsible for inflammation and pain) inhibitors designed to increase the anti-cancer potency and effectiveness of chemotherapy safely, offering new treatment options for patients suffering from colorectal, non-small cell lung and pancreatic cancers.
Learn more… Account Required

Immunophotonics, Inc., based in St. Louis, MO, is an early stage biotechnology company engaged in the development of a proprietary drug product for use in a minimally invasive therapeutic cancer vaccine (inCVAX) for the treatment of metastatic tumors. The approach is intended to trigger the body’s own anti-tumor immune response against cancerous cells. For more information, see http://www.immunophotonics.com.
Learn more… Account Required

Tansna Therapeutics, Inc., based in St. Louis, MO, is developing and testing anticonvulsant drugs for the treatment of epilepsy. Worldwide, at least 50 million people suffer from epilepsy, 30% of whom are unable to achieve adequate seizure control using existing medications. Tansna’s proprietary anticonvulsant compounds have been shown in animal testing to prevent seizures in such otherwise therapy-resistant patients.
Learn more… Account Required

Selection Team

Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont, brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor of the blockbuster COX-2 in …

A Once-in-a-Lifetime Opportunity in Healthcare Is Here

Healthcare is going through a major transition phase and is ripe for innovation, that much we know for sure. We also know that innovation comes from talented leadership, backed by smart investors.

Join our healthcare market network.

iSelect Companies

Selection Team

Read More from iSelect

Register to Learn More